Colon Targeting: Why and How?

0:00Welcome to Creative Biolapse's podcast channel. Join us as we explore the cutting-edge science of targeted delivery systems that are revolutionizing medicine. Interested in the future of drug development? Subscribe now. Hello and welcome back to the Pharma Frontier, the podcast where we explore the cutting edge of drug delivery. I'm your host, Alex. Today, we embark on an exciting three-part series diving deep into a very specialized area, getting drugs exactly where they need to go in our gut, specifically the colon. To guide us through this complex journey, I'm thrilled to be joined by our resident expert in advanced drug delivery systems, Dr. Lena Cruz. Welcome back, Lena. Thanks, Alex. It's great to be here. This is a fascinating topic with significant implications for treating a range of debilitating diseases. Absolutely. So, let's set the stage. Why is there such a focus on specifically targeting the

1:00colon with medications? It seems like a very specific destination. It is specific and for good reasons. Think about diseases like ulcerative colitis, Crohn's disease, and colon cancer. These are conditions that directly affect the colon. Delivering drugs directly to the site of inflammation or the tumor can maximize the local therapeutic effect while minimizing systemic side effects. For example, a steroid like Dudescanide works best right where the inflammation is, in the colon, not circulating throughout the entire body. That makes sense for local action. But the chapter also mentions systemic delivery from the colon. Why deliver a drug for systemic effect from so far down the track? Excellent question. There are two key advantages. First, bypassing what we call first pass metabolism. When you swallow a pill, it's absorbed and goes straight to the liver via the portal vein.

2:01The liver can metabolize or break down a lot of the drug before it even reaches your general circulation. The colon has a different blood supply that bypasses this initial liver metabolism, which can potentially increase the drug's bioavailability for some compounds. So, you get more active drug into the bloodstream? Potentially, yes. The second reason is to protect the upper gastrointestinal tract. Drugs like non-steroidal anti-inflammatory drugs, or NSAIDs, can cause gastric irritation and ulcers. If we can design a system that only releases the drug in the colon, we might avoid those upper GI side effects. I see. But isn't the colon designed to absorb water in salts? How good is it at absorbing different drugs? You've hit on a fundamental challenge, Alex. The colon's primary job is water absorption, not necessarily optimal drug absorption. Early studies showed this variability. For instance, a drug called glybanclamide was absorbed

3:06in the stomach, duodenum, and colon, but the rate of absorption was different in each place. Another study on theophiline found it was absorbed in multiple areas, but its half-life in the colon was twice as long as elsewhere. What does a longer half-life in the colon mean for treatment? It suggests the drug stays around longer at that site, which could be beneficial for sustained action. But overall, these findings told researchers that to reliably and specifically target the colon, they couldn't rely on the colon's natural absorption for many drugs. They needed smarter delivery systems, often involving pro-drugs. Pro-drugs come up a lot in this field. Can you remind our listeners what a pro-drug is? Of course. Think of a pro-drug as a disguised or inactive version of the active drug. It's like a sleeper agent. The pro-drug is designed to travel safely through the body without doing much. Only when it reaches its specific target location,

4:08in this case, the colon does it get activated or switched on to become the therapeutic drug. This activation is triggered by something unique to the colon. So, the key is finding that unique trigger in the colon that is in present earlier in the digestive journey. Precisely. And the colon offers several unique physiological features we can exploit. Let's talk about transit time first. The entire journey from mouth to anus can take one to three days. But critically, the small intestine transit is relatively quick and consistent about three hours. So, a delivery system needs to survive the stomach and this three hour small intestine journey intact, and then release its payload quickly once it hits the colon. That's a tight schedule. It has to be a sturdy traveler. It does. But the real magic lies in the colon's unique environment. First, and perhaps most important, is the microflora.

5:09The colon is teaming with billions of bacteria, a vast and diverse ecosystem not found in such density in the stomach or small intestine. We usually think of bacteria as something to avoid, but here they're helpful. In this context, absolutely. These bacteria produce a unique set of enzymes to break down materials. For drug delivery, this is a gold mine. We can design per drugs that are stable against our human digestive enzymes, but are specifically cleaved by these bacterial enzymes. It's like having a secret key that only the colonic bacteria possess. That's a brilliant strategy. What other features define the colon? The second feature is pH. The stomach is extremely acidic, with a pH around 1 to 2. The small intestine is more neutral, around 6.6 to 7.5. Research using special radiate olemetry capsules has shown the pH in the colon is slightly more neutral to slightly acidic, generally ranging from 6.4 to 7.0.

6:14So, we can design coatings or materials that dissolve only in this specific pH range. So, a coating that stays intact in the acidic stomach and the neutral small intestine, but dissolves in the near-neutral colon? Exactly. The third feature is pressure and viscosity. The colon is actively reabsorbing water, so its contents are more viscous, thicker. It also generates strong peristaltic waves, which are muscular contractions to move material along. This allows for pressure-controlled systems, a capsule with a special wall that won't dissolve, but will rupture under the specific pressure of these colonic contractions. So, we have three main triggers, bacterial enzymes, pH and pressure, and the chapter groups the strategies around these. Yes, that's a great way to frame it. The main colon-specific delivery methods outlined are, one, microbially triggered release, which uses the bacterial enzymes. Two, pH-sensitive polymer systems for time-dependent release.

7:18Three, osmotic release systems. Four, pressure-controlled delivery. And five, the emerging field of nanoparticle approaches that can incorporate any of these mechanisms. Before we dive into each method, the chapter mentions a historical prodrug, Prontosil. What's its significance? Prontosil is a wonderful piece of history. Developed in the 1930s, it was the first commercially available antimicrobial prodrug. It's an azolinked compound. In the body, specifically in tissues with the right enzymes, the azobond was cleaved to release the active antibiotic sulfanilamide. While not initially designed for the colon, it laid the groundwork. Researchers realized that azobonds are particularly susceptible to reduction by specific enzymes called azoreductases, which are abundant in the colonic bacterial flora. So, Prontosil was the prototype that inspired colon targeting?

8:19In many ways, yes. The most successful modern descendants of this idea are drugs for inflammatory bowel disease. A classic example is sulfosalazine, developed in the 1950s. It links an anti-inflammatory agent, five amino-salacillic acid, to an antibiotic sulfapyridine, vien-azobond. The intact prodrug travels to the colon, where bacterial azoreductases cleave the bond, releasing five amino-salacillic acid right at the site of inflammation. And that's more effective than just taking five amino-salacillic acid orally? Much more. If you take five amino-salacillic acid alone, it's absorbed high up in the small intestine and never reaches the colon in meaningful amounts. The prodrug ensures targeted delivery. However, sulfosalazine had side effects from the sulfapyridine part. This led to newer azoprodrugs like alzine, which is essentially two molecules of the active drug

9:20linked by an azobond. A 1992 clinical trial showed alzine was better at preventing relapse in ulcerative colitis patients than five amino-salacillic acid alone. So, the principle is solid. Use a bond only colonic bacteria can break. Are there other bacterial enzyme targets besides azoreductase? Many. Another major approach uses glycosodases and glucuronodases. These enzymes break down sugar molecules. The upper gastrointestinal tract doesn't absorb larger sugar conjugates well, but colonic bacteria love to break them apart. So, researchers attach drugs to sugar molecules like glucose or glucuronic acid, creating prodrugs like dexamethasone glucoside. Animal studies showed a much higher percentage of the prodrug reached the seechum, a part of the large intestine, compared to the free drug. And once there, the bacteria chew off the sugar, releasing the steroid.

10:21Correct. Similarly, amino acids can be used as linkers. The idea is to create an amide bond between an amino acid and a drug, like linking glycine to a non-steroidal anti-inflammatory drug. This bond should be stable in the upper gastrointestinal tract but cleavable in the colon. Successful conjugates have shown negligible drug release during the upper gastrointestinal passage and maximum release in simulated colonic conditions. It sounds like microbially triggered release is the most common and perhaps most specific strategy. It is often considered the most colon specific because it directly exploits the most unique feature of the colon, its microflora. However, it's not without potential drawbacks. For example, the bacterial breakdown of some sugar moieties could theoretically release unexpected or toxic metabolites, though this is carefully evaluated. This has been a fantastic overview, Lena. We've covered the why of colon targeting and dipped into the how with microbially activated

11:25prodrugs. In our next episode, we'll delve into the other major strategies, pH sensitive systems and osmotic release. I look forward to it, Alex. These approaches showcase the incredible ingenuity in formulation science to meet physiological challenges. Listeners, join us next time on the pharma frontier as we continue our journey into colon-targeted drug delivery. Until then, stay curious.